Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Tisotumab Vedotin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TIVDAK® approved by European Commission for Cervical Cancer
    TIVDAK® approved by European Commission for Cervical Cancer

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Tivdak approved by Japan Ministry for Advanced Cervical Cancer
    Tivdak approved by Japan Ministry for Advanced Cervical Cancer

    27 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250326627819/en/TIVDAK-tisotumab-vedotin-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-for-the-Treatment-of-Advanced-or-Recurrent-Cervical-Cancer-that-has-Progressed-on-or-after-Chemotherapy

    BUSINESSWIRE
    27 Mar 2025
    Share Share
    Zai Lab Achieves Milestone In Cervical Cancer Treatment Study
    Zai Lab Achieves Milestone In Cervical Cancer Treatment Study

    15 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250115437262/en

    BUSINESSWIRE
    15 Jan 2025
    Share Share
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603640244/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC
    Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892268/0/en/Investigational-Tisotumab-Vedotin-Phase-2-Data-Demonstrates-Encouraging-Antitumor-Activity-in-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Squamous-Cell-Carcinoma-HNSCC.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    US FDA grants full approval for Pfizer's cervical cancer drug
    US FDA grants full approval for Pfizer's cervical cancer drug

    30 Apr 2024

    // Pratik Jain REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-full-approval-pfizers-cervical-cancer-drug-2024-04-29/

    Pratik Jain REUTERS
    30 Apr 2024
    Share Share